The estimated Net Worth of Kieran Gallahue is at least $3.33 Milion dollars as of 23 February 2024. Mr. Gallahue owns over 7,056 units of Intersect ENT Inc stock worth over $303,778 and over the last 20 years he sold XENT stock worth over $0. In addition, he makes $3,025,240 as Non-Executive Chairman of the Board at Intersect ENT Inc.
Kieran has made over 48 trades of the Intersect ENT Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 7,056 units of XENT stock worth $260,084 on 23 February 2024.
The largest trade he's ever made was exercising 50,000 units of Intersect ENT Inc stock on 10 November 2006 worth over $799,500. On average, Kieran trades about 7,624 units every 81 days since 2004. As of 23 February 2024 he still owns at least 10,757 units of Intersect ENT Inc stock.
You can see the complete history of Mr. Gallahue stock trades at the bottom of the page.
Kieran T. Gallahue serves as Non-Executive Chairman of the Board of the Company. He served as a member of our Board since April 2015. Mr. Gallahue served as our Lead Director from April 2015 until May 2019, has served as Executive Chairman of the Board since May 2019 (which term will end at the end of April 2020), and served as Interim President and Chief Executive Officer, or CEO, from June 2019 through July 2019. The Board has appointed Mr. Gallahue to serve as our Chairman of the Board beginning in May 2020. Mr. Gallahue served as Chairman and Chief Executive Officer of CareFusion Corporation, a global healthcare company from February 2011 until its sale in March 2015. From January 2008 through January 2011, Mr. Gallahue served as Chief Executive Officer and as a Director of ResMed Inc., a medical device company. Mr. Gallahue has also served as a member of the board of directors of Envista Holdings, a dental technology company, since 2019, Arena Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, since July 2018, and Edwards Lifesciences Corporation, a cardiovascular device company, since February 2015.
As the Non-Executive Chairman of the Board of Intersect ENT Inc, the total compensation of Kieran Gallahue at Intersect ENT Inc is $3,025,240. There are 1 executives at Intersect ENT Inc getting paid more, with Thomas West having the highest compensation of $7,206,100.
Kieran Gallahue is 56, he's been the Non-Executive Chairman of the Board of Intersect ENT Inc since 2020. There are 12 older and no younger executives at Intersect ENT Inc. The oldest executive at Intersect ENT Inc is Frederic Moll, 68, who is the Independent Director.
Kieran's mailing address filed with the SEC is C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD., BLDG. E, BREA, CA, 92821.
Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt oraz W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
Intersect ENT Inc executives and other stock owners filed with the SEC include: